Abstract
Summary
Venom Antiserum is a medication made from antibodies which is used to treat certain venomous bites and stings. They are recommended only if there is significant toxicity or a high risk of toxicity. The specific Venom Antiserum needed depends on the species involved. It is given by injection.
LPI (LP Information)' newest research report, the “Venom Antiserum Industry Forecast” looks at past sales and reviews total world Venom Antiserum sales in 2022, providing a comprehensive analysis by region and market sector of projected Venom Antiserum sales for 2023 through 2029. With Venom Antiserum sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Venom Antiserum industry.
This Insight Report provides a comprehensive analysis of the global Venom Antiserum landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Venom Antiserum portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Venom Antiserum market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Venom Antiserum and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Venom Antiserum.
The global Venom Antiserum market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Venom Antiserum is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Venom Antiserum is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Venom Antiserum is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Venom Antiserum players cover CSL, Merck, BTG, Pfizer, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, Vins Bioproducts and Bharat Serums and Vaccines, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Venom Antiserum market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Polyvalent
Monovalent
Segmentation by application
Hospitals and Clinics
Non-profit Institutions
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
CSL
Merck
BTG
Pfizer
Haffkine Bio-Pharmaceutical
Rare Disease Therapeutics
Flynn Pharma
Vins Bioproducts
Bharat Serums and Vaccines
Serum Biotech
MicroPharm
Key Questions Addressed in this Report
What is the 10-year outlook for the global Venom Antiserum market?
What factors are driving Venom Antiserum market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Venom Antiserum market opportunities vary by end market size?
How does Venom Antiserum break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
LPI (LP Information)' newest research report, the “Venom Antiserum Industry Forecast” looks at past sales and reviews total world Venom Antiserum sales in 2022, providing a comprehensive analysis by region and market sector of projected Venom Antiserum sales for 2023 through 2029. With Venom Antiserum sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Venom Antiserum industry.
This Insight Report provides a comprehensive analysis of the global Venom Antiserum landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Venom Antiserum portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Venom Antiserum market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Venom Antiserum and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Venom Antiserum.
The global Venom Antiserum market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Venom Antiserum is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Venom Antiserum is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Venom Antiserum is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Venom Antiserum players cover CSL, Merck, BTG, Pfizer, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, Vins Bioproducts and Bharat Serums and Vaccines, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Venom Antiserum market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Polyvalent
Monovalent
Segmentation by application
Hospitals and Clinics
Non-profit Institutions
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
CSL
Merck
BTG
Pfizer
Haffkine Bio-Pharmaceutical
Rare Disease Therapeutics
Flynn Pharma
Vins Bioproducts
Bharat Serums and Vaccines
Serum Biotech
MicroPharm
Key Questions Addressed in this Report
What is the 10-year outlook for the global Venom Antiserum market?
What factors are driving Venom Antiserum market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Venom Antiserum market opportunities vary by end market size?
How does Venom Antiserum break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Venom Antiserum Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Venom Antiserum by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Venom Antiserum by Country/Region, 2018, 2022 & 2029
2.2 Venom Antiserum Segment by Type
2.2.1 Polyvalent
2.2.2 Monovalent
2.3 Venom Antiserum Sales by Type
2.3.1 Global Venom Antiserum Sales Market Share by Type (2018-2023)
2.3.2 Global Venom Antiserum Revenue and Market Share by Type (2018-2023)
2.3.3 Global Venom Antiserum Sale Price by Type (2018-2023)
2.4 Venom Antiserum Segment by Application
2.4.1 Hospitals and Clinics
2.4.2 Non-profit Institutions
2.5 Venom Antiserum Sales by Application
2.5.1 Global Venom Antiserum Sale Market Share by Application (2018-2023)
2.5.2 Global Venom Antiserum Revenue and Market Share by Application (2018-2023)
2.5.3 Global Venom Antiserum Sale Price by Application (2018-2023)
3 Global Venom Antiserum by Company
3.1 Global Venom Antiserum Breakdown Data by Company
3.1.1 Global Venom Antiserum Annual Sales by Company (2018-2023)
3.1.2 Global Venom Antiserum Sales Market Share by Company (2018-2023)
3.2 Global Venom Antiserum Annual Revenue by Company (2018-2023)
3.2.1 Global Venom Antiserum Revenue by Company (2018-2023)
3.2.2 Global Venom Antiserum Revenue Market Share by Company (2018-2023)
3.3 Global Venom Antiserum Sale Price by Company
3.4 Key Manufacturers Venom Antiserum Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Venom Antiserum Product Location Distribution
3.4.2 Players Venom Antiserum Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Venom Antiserum by Geographic Region
4.1 World Historic Venom Antiserum Market Size by Geographic Region (2018-2023)
4.1.1 Global Venom Antiserum Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Venom Antiserum Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Venom Antiserum Market Size by Country/Region (2018-2023)
4.2.1 Global Venom Antiserum Annual Sales by Country/Region (2018-2023)
4.2.2 Global Venom Antiserum Annual Revenue by Country/Region (2018-2023)
4.3 Americas Venom Antiserum Sales Growth
4.4 APAC Venom Antiserum Sales Growth
4.5 Europe Venom Antiserum Sales Growth
4.6 Middle East & Africa Venom Antiserum Sales Growth
5 Americas
5.1 Americas Venom Antiserum Sales by Country
5.1.1 Americas Venom Antiserum Sales by Country (2018-2023)
5.1.2 Americas Venom Antiserum Revenue by Country (2018-2023)
5.2 Americas Venom Antiserum Sales by Type
5.3 Americas Venom Antiserum Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Venom Antiserum Sales by Region
6.1.1 APAC Venom Antiserum Sales by Region (2018-2023)
6.1.2 APAC Venom Antiserum Revenue by Region (2018-2023)
6.2 APAC Venom Antiserum Sales by Type
6.3 APAC Venom Antiserum Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Venom Antiserum by Country
7.1.1 Europe Venom Antiserum Sales by Country (2018-2023)
7.1.2 Europe Venom Antiserum Revenue by Country (2018-2023)
7.2 Europe Venom Antiserum Sales by Type
7.3 Europe Venom Antiserum Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Venom Antiserum by Country
8.1.1 Middle East & Africa Venom Antiserum Sales by Country (2018-2023)
8.1.2 Middle East & Africa Venom Antiserum Revenue by Country (2018-2023)
8.2 Middle East & Africa Venom Antiserum Sales by Type
8.3 Middle East & Africa Venom Antiserum Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Venom Antiserum
10.3 Manufacturing Process Analysis of Venom Antiserum
10.4 Industry Chain Structure of Venom Antiserum
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Venom Antiserum Distributors
11.3 Venom Antiserum Customer
12 World Forecast Review for Venom Antiserum by Geographic Region
12.1 Global Venom Antiserum Market Size Forecast by Region
12.1.1 Global Venom Antiserum Forecast by Region (2024-2029)
12.1.2 Global Venom Antiserum Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Venom Antiserum Forecast by Type
12.7 Global Venom Antiserum Forecast by Application
13 Key Players Analysis
13.1 CSL
13.1.1 CSL Company Information
13.1.2 CSL Venom Antiserum Product Portfolios and Specifications
13.1.3 CSL Venom Antiserum Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 CSL Main Business Overview
13.1.5 CSL Latest Developments
13.2 Merck
13.2.1 Merck Company Information
13.2.2 Merck Venom Antiserum Product Portfolios and Specifications
13.2.3 Merck Venom Antiserum Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Merck Main Business Overview
13.2.5 Merck Latest Developments
13.3 BTG
13.3.1 BTG Company Information
13.3.2 BTG Venom Antiserum Product Portfolios and Specifications
13.3.3 BTG Venom Antiserum Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 BTG Main Business Overview
13.3.5 BTG Latest Developments
13.4 Pfizer
13.4.1 Pfizer Company Information
13.4.2 Pfizer Venom Antiserum Product Portfolios and Specifications
13.4.3 Pfizer Venom Antiserum Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Pfizer Main Business Overview
13.4.5 Pfizer Latest Developments
13.5 Haffkine Bio-Pharmaceutical
13.5.1 Haffkine Bio-Pharmaceutical Company Information
13.5.2 Haffkine Bio-Pharmaceutical Venom Antiserum Product Portfolios and Specifications
13.5.3 Haffkine Bio-Pharmaceutical Venom Antiserum Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Haffkine Bio-Pharmaceutical Main Business Overview
13.5.5 Haffkine Bio-Pharmaceutical Latest Developments
13.6 Rare Disease Therapeutics
13.6.1 Rare Disease Therapeutics Company Information
13.6.2 Rare Disease Therapeutics Venom Antiserum Product Portfolios and Specifications
13.6.3 Rare Disease Therapeutics Venom Antiserum Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Rare Disease Therapeutics Main Business Overview
13.6.5 Rare Disease Therapeutics Latest Developments
13.7 Flynn Pharma
13.7.1 Flynn Pharma Company Information
13.7.2 Flynn Pharma Venom Antiserum Product Portfolios and Specifications
13.7.3 Flynn Pharma Venom Antiserum Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Flynn Pharma Main Business Overview
13.7.5 Flynn Pharma Latest Developments
13.8 Vins Bioproducts
13.8.1 Vins Bioproducts Company Information
13.8.2 Vins Bioproducts Venom Antiserum Product Portfolios and Specifications
13.8.3 Vins Bioproducts Venom Antiserum Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Vins Bioproducts Main Business Overview
13.8.5 Vins Bioproducts Latest Developments
13.9 Bharat Serums and Vaccines
13.9.1 Bharat Serums and Vaccines Company Information
13.9.2 Bharat Serums and Vaccines Venom Antiserum Product Portfolios and Specifications
13.9.3 Bharat Serums and Vaccines Venom Antiserum Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Bharat Serums and Vaccines Main Business Overview
13.9.5 Bharat Serums and Vaccines Latest Developments
13.10 Serum Biotech
13.10.1 Serum Biotech Company Information
13.10.2 Serum Biotech Venom Antiserum Product Portfolios and Specifications
13.10.3 Serum Biotech Venom Antiserum Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Serum Biotech Main Business Overview
13.10.5 Serum Biotech Latest Developments
13.11 MicroPharm
13.11.1 MicroPharm Company Information
13.11.2 MicroPharm Venom Antiserum Product Portfolios and Specifications
13.11.3 MicroPharm Venom Antiserum Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 MicroPharm Main Business Overview
13.11.5 MicroPharm Latest Developments
14 Research Findings and Conclusion